All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View MPN content recommended for you
Has the GEM-CESAR study demonstrated that early intervention in SMM should be a new SOC?
Featured:
María-Victoria MateosThe Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, María Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, answers the question: Has the GEM-CESAR study demonstrated that early intervention in smoldering multiple myeloma should be a new standard of care?
María Victoria Mateos talks about the results of the GEM-CESAR study that was conducted in high-risk smoldering multiple myeloma patients with the aim to offer a curative option for these asymptomatic patients. She discusses the treatment regimen of the study arms and states the MRD-status was monitored to measure patient response to treatment.
Has the GEM-CESAR study demonstrated that early intervention in SMM should be a new SOC?
Your opinion matters
HCPs, which of the following best characterizes your perception of belantamab mafodotin in combination (BVd, BPd) for the treatment of relapsed/refractory multiple myeloma?